Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Authors

Matthew Ellis

Published

February 23, 2017

Loading PDF viewer…

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pathology And Forensic Medicine

DOI

10.1200/jco.2016.69.4406

License

CC-BY-NC-ND

Other Formats

PDF

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Authors

Matthew Ellis

Published

February 23, 2017

Loading PDF viewer…

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pathology And Forensic Medicine

DOI

10.1200/jco.2016.69.4406

License

CC-BY-NC-ND

Other Formats

PDF

Paper

Paper

Paper

Paper

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Supporters

Journal

Topics

DOI

License

Other Formats

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Supporters

Journal

Topics

DOI

License

Other Formats

Supporters

Journal

Topics

DOI

License

Other Formats